News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Medical Imaging, Inc. (BMY) Awarded Three-Year Contract For Definity(R) By Premier


10/19/2005 5:13:02 PM

N. BILLERICA, Mass., April 21 /PRNewswire/ -- Bristol-Myers Squibb Medical Imaging today announced that Premier Purchasing Partners, L.P., the group purchasing division of Premier Inc., has awarded Bristol-Myers Squibb Medical Imaging a three-year, sole source contract for Definity(R) (Vial for Perflutren Lipid Microsphere Injectable Suspension) -- the leading echocardiography contrast agent in the United States.

Under the terms of the agreement, Bristol-Myers Squibb Medical Imaging will offer Definity to Premier's 1,500 hospital facilities and hundreds of other affiliated healthcare sites throughout the United States. The agreement is in effect through December 31, 2007.

"As leaders in the field of cardiovascular imaging, we are very pleased to enter into this agreement with Premier -- another innovator in the healthcare industry," said Cory Zwerling, president, Bristol-Myers Squibb Medical Imaging. "Most importantly, we look forward to working with Premier to bring the benefits of Definity to the patients served throughout its leading network of facilities in the United States."

In patients with suboptimal echocardiograms, Definity enables physicians to visualize the borders of the heart more clearly. By improving the visualization of the primary pumping chamber of the heart, Definity-enhanced echocardiography may improve the ability to evaluate left ventricular wall motion -- a critical indicator of heart function.

Important Safety Information About Definity(R)

Activated Definity should not be administered in patients with known cardiac shunts nor by direct intra-arterial injection. Extreme caution should be exercised in patients who may have cardiac shunts and in those with chronic pulmonary vascular disorders. The safety of activated Definity at mechanical indices of > 0.8 and with end-systolic triggering has not been established.

Administration of activated Definity(R) (Vial for Perflutren Lipid Microsphere Injectable Suspension) occasionally may be associated with QTc prolongation. The overall incidence of treatment-related adverse events was 8.4 percent and those reported most frequently included headache, back or renal pain, flushing, nausea, chest pain and dizziness. Definity will not be properly activated, and must not be used, unless it has completed the 45 second Vialmix(R) activation.

About Premier, Inc.

Premier, Inc. is a major strategic alliance in U.S. healthcare entirely owned by more than 200 of the nation's leading hospital and healthcare systems. These systems operate or are affiliated with more than 1,500 hospital facilities and hundreds of other care sites. Premier provides an array of resources supporting performance improvement in healthcare delivery, such as comprehensive supply chain management resources including group purchasing for more than $21 billion annually in supplies and equipment. Other improvement services include clinical performance initiatives, comparative databases and related applications, capital life-cycle management, insurance programs, and practice management support. Premier is headquartered in San Diego, California, with major office locations in Chicago, Illinois, Charlotte, North Carolina, and Washington, D.C. For more information, visit http://www.premierinc.com/.

About Bristol-Myers Squibb Medical Imaging

Bristol-Myers Squibb Medical Imaging Inc. is a worldwide leader in cardiovascular imaging whose mission is to extend and enhance human life by offering innovative approaches to see deeper into the heart and vasculature. Bristol-Myers Squibb Medical Imaging is a wholly-owned subsidiary of Bristol- Myers Squibb Company , a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life. For more information on Bristol-Myers Squibb Medical Imaging, visit http://www.bmsmi.com/.

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, market factors, competitive product development, governmental regulations and legislation, patent positions and litigation. No forward- looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2004 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Definity(R) and Vialmix(R) are registered trademarks of Bristol-Myers Squibb Medical Imaging Inc.

Contact: Lili Gordon 978-671-8924 lili.gordon@bms.com

Bristol-Myers Squibb Medical Imaging Inc.

CONTACT: Lili Gordon of Bristol-Myers Squibb Medical Imaging Inc.,+1-978-671-8924, lili.gordon@bms.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES